Buscar
01/07/2025
Analytical Interference of Exemestane with Androstenedione Immunoassays
Giralt, M, Ferrer, R, Díaz-Troyano, N, Vega, B, Luque-Ramírez, M, Martínez, S, Fernández, B, Martínez, I, Fabregat, A, Urgell, E, Cardona, I, Casals, G, Escobar-Morreale, HF. Analytical Interference of Exemestane with Androstenedione Immunoassays. Annals of Laboratory Medicine. 2025; 45(4)DOI:10.3343/alm.2024.0362. PMID:40114653. IF:3.900(Q1/1D).
01/09/2024
Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis
Fernandez-Bravo, S, Canyelles, M, Martín-Blázquez, A, Borràs, C, Nuñez-Borque, E, Palacio-García, L, Del Rio, PR, Betancor, D, Gómez-López, A, Brescó, MS, Laguna, JJ, Méndez-Barbero, N, Rotllan, N, Escolà-Gil, JC, Esteban, V. Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2024; 154(3)DOI:10.1016/j.jaci.2024.03.031. PMID:38718948. IF:11.200(Q1/1D).
01/08/2024
IN VITRO AND IN VIVO EFFECTS OF LIVER X RECEPTOR AND CHOLESTEROL LOADING IN VASCULAR SMOOTH MUSCULAR CELL-SPECIFIC REVERSE CHOLESTEROL TRANSPORT
Velasco, L, Querol, CB, Santos, D, Rotllan, N, Tondo, M, Camacho, M, Blanco-Vaca, F, Escolà-Gil, JC, Canyelles, M. IN VITRO AND IN VIVO EFFECTS OF LIVER X RECEPTOR AND CHOLESTEROL LOADING IN VASCULAR SMOOTH MUSCULAR CELL-SPECIFIC REVERSE CHOLESTEROL TRANSPORT. ATHEROSCLEROSIS. 2024; 395DOI:. PMID:. IF:5.700(Q1/1D).
01/08/2024
HDL PROTEOME ASSOCIATES WITH HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE AND CHOLESTEROL EFFLUX CAPACITY IN METABOLIC SYNDROME PATIENTS
Grao-Cruces, E, Mocciaro, G, Marquez-Paradas, E, Santos-Mejias, A, Canyelles, M, Escola-Gil, JC, Martin-Rubio, ME, La Paz, SMD. HDL PROTEOME ASSOCIATES WITH HEPATIC AND ADIPOSE TISSUE INSULIN RESISTANCE AND CHOLESTEROL EFFLUX CAPACITY IN METABOLIC SYNDROME PATIENTS. ATHEROSCLEROSIS. 2024; 395DOI:. PMID:. IF:5.700(Q1/1D).
31/07/2024
Improvement of non-adherence and reduction of BP values in patients with difficult-to-treat hypertension: the ATHAN clinical trial
Oliveras, A, Vázquez, S, Vega, MV, Camps, C, Illana, FJ, Armario, P, Crespo, M, de la Sierra, A. Improvement of non-adherence and reduction of BP values in patients with difficult-to-treat hypertension: the ATHAN clinical trial. HYPERTENSION RESEARCH. 2024; DOI:10.1038/s41440-024-01748-x. PMID:39085464. IF:4.600(Q1/2D).
01/07/2024
Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice
Delgado-Lista, J, Mostaza, JM, Arrobas-Velilla, T, Blanco-Vaca, F, Masana, L, Pedro-Botet, J, Perez-Martinez, P, Civeira, F, Cuende-Melero, JI, Gomez-Barrado, JJ, Lahoz, C, Pinto, X, Suarez-Tembra, M, Lopez-Miranda, J, Guijarro, C. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice. Clinica E Investigacion En Arteriosclerosis. 2024; 36(4)DOI:10.1016/j.arteri.2024.03.002. PMID:38599943. IF:(Q/D).
17/06/2024
Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis
La Lhoëst, MTL, Martinez, A, Claudi, L, Garcia, E, Benitez-Amaro, A, Polishchuk, A, Piñero, J, Vilades, D, Guerra, JM, Sanz, F, Rotllan, N, Escolà-Gil, JC, Llorente-Cortés, V. Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis. Frontiers in Cardiovascular Medicine. 2024; 11DOI:10.3389/fcvm.2024.1381520. PMID:38952543. IF:2.900(Q2/4D).
01/06/2024
Apolipoproteins and Lipoproteins in Health and Disease 2.0
Rotllan, N, Escolà-Gil, JC. Apolipoproteins and Lipoproteins in Health and Disease 2.0. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(11)DOI:10.3390/ijms25116183. PMID:38892369. IF:4.900(Q1/3D).
01/06/2024
Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes
Illana, FJ, García-Osuna, A, Sospedra, M, Ferrer, R, Martínez-Brú, C, Guiñón, L. Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes. Biochemia Medica. 2024; 34(2)DOI:10.11613/BM.2024.020704. PMID:38665870. IF:1.800(Q3/6D).
01/06/2024
Inhibitory effects of LRP1-based immunotherapy on cardiac extracellular matrix biophysical alterations induced by hypercholesterolemia
Lhoëst, MTL, Samouillan, V, García, E, Amaro, AB, Dandurand, J, Dato, VA, Guerra, JM, Escolà-Gil, JC, Chiabrando, G, Enrich, C. Inhibitory effects of LRP1-based immunotherapy on cardiac extracellular matrix biophysical alterations induced by hypercholesterolemia. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
29/05/2024
Decreased atherosclerosis and abdominal aortic aneurysm in mice deficient in polymeric immunoglobulin receptor
Pardo, IC, Botija, BP, Garcia, AG, Villanueva, LO, Folgado, IM, Raposo,, Mur, S, Robles,, Gil, JCE, Nunez, E, Sancho, D, Vazquez, J, Colio, LMB, Ramiro, A, Ventura, JLM. Decreased atherosclerosis and abdominal aortic aneurysm in mice deficient in polymeric immunoglobulin receptor. CARDIOVASCULAR RESEARCH. 2024; 120DOI:10.1093/cvr/cvae088.161. PMID:. IF:13.300(Q1/1D).
29/05/2024
Role of polymeric immunoglobulin receptor in glucose metabolism
Botija, MP, Pardo, IC, Garcia, AG, Villanueva, LO, Colio, LB, Ramiro, A, Gil, JCE, Ventura, JLM. Role of polymeric immunoglobulin receptor in glucose metabolism. CARDIOVASCULAR RESEARCH. 2024; 120DOI:10.1093/cvr/cvae088.192. PMID:. IF:13.300(Q1/1D).
01/01/2024
Hydroxytyrosol Induces Dyslipidemia in an ApoB100 Humanized Mouse Model
de las Hazas, MCL, del Saz-Lara, A, Cedó, L, Crespo, MC, Tomé-Carneiro, J, Chapado, LA, Macià, A, Visioli, F, Escola-Gil, JC, Dávalos, A. Hydroxytyrosol Induces Dyslipidemia in an ApoB100 Humanized Mouse Model. MOLECULAR NUTRITION & FOOD RESEARCH. 2024; 68(1)DOI:10.1002/mnfr.202300508. PMID:37933702. IF:4.200(Q1/3D).
14/12/2023
Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation
Martinez-Campanario, MC, Cortés, M, Moreno-Lanceta, A, Han, L, Ninfali, C, Domínguez, V, Andrés-Manzano, MJ, Farràs, M, Esteve-Codina, A, Enrich, C, Diaz-Crespo, FJ, Pintado, B, Escolà-Gil, JC, de Frutos, PG, Andrés, V, Melgar-Lesmes, P, Postigo, A. Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-43896-7. PMID:38097578. IF:14.700(Q1/1D).
01/11/2023
Characterization of add-on testing before and after automation at a core laboratory
García-Osuna, A, Muñoz, LG, Pallaruelo, MC, Usero, AM, Eduardo, BC, Ramos, JL, Canyelles, M, Brú, CM, Cámara, FJI. Characterization of add-on testing before and after automation at a core laboratory. Heliyon. 2023; 9(11)DOI:10.1016/j.heliyon.2023.e22096. PMID:38034602. IF:3.400(Q1/3D).
27/10/2023
Systems biology and data-driven machine learning-based models in personalized cardiovascular medicine
Hueso, M, Rotllan, N, Escolà-Gil, JC, Vellido, A. Systems biology and data-driven machine learning-based models in personalized cardiovascular medicine. Frontiers in Cardiovascular Medicine. 2023; 10DOI:10.3389/fcvm.2023.1320110. PMID:37965080. IF:2.800(Q2/4D).
12/10/2023
Periodic verification of results' comparability between several analyzers: Experience in the application of the EP31-A-IR guideline
Guiñón L., Illana F.J., Cuevas B., Canyelles M., Martínez-Bru C., García-Osuna Á.. Periodic verification of results' comparability between several analyzers: Experience in the application of the EP31-A-IR guideline. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2023; 62(3)DOI:10.1515/cclm-2023-0994. PMID:37819627. IF:3.800(Q1/2D).
01/08/2023
Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism
Lee-Rueckert, M, Canyelles, M, Tondo, M, Rotllan, N, Kovanen, PT, Llorente-Cortes, V, Escola-Gil, JC. Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. SEMINARS IN CANCER BIOLOGY. 2023; 93DOI:10.1016/j.semcancer.2023.05.002. PMID:37156344. IF:12.100(Q1/1D).
01/06/2023
"MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression"
Frutos, MFD, Pardo-Marques, V, Torrecilla-Parra, M, Rada, P, Perez-Garcia, A, Martin-Martin, Y, de la Pena, G, Gomez, A, Toledano-Zaragoza, A, Gomez-Coronado, D, Casarejos, MJ, Solis, JM, Rotllan, N, Pastor, O, Ledesma, MD, Valverde, AM, Busto, R, Ramirez, CM. "MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression". Biochimica et Biophysica Acta-Gene Regulatory Mechanisms. 2023; 1866(2)DOI:10.1016/j.bbagrm.2023.194938. PMID:37086967. IF:2.600(Q3/6D).
11/05/2023
Inhibitory Effects of LRP1-Based Immunotherapy on Cardiac Extracellular Matrix Biophysical Alterations Induced by Hypercholesterolemia
Samouillan, V, Garcia, E, Benitez-Amaro, A, Lhoest, MTLC, Dandurand, J, Dato, VA, Guerra, JM, Escola-Gil, JC, Chiabrando, G, Enrich, C, Llorente-Cortes, V. Inhibitory Effects of LRP1-Based Immunotherapy on Cardiac Extracellular Matrix Biophysical Alterations Induced by Hypercholesterolemia. JOURNAL OF MEDICINAL CHEMISTRY. 2023; 66(9)DOI:10.1021/acs.jmedchem.2c02103. PMID:37116069. IF:6.900(Q1/1D).